Back to Agenda
Session 7 Track 3: Taking a Peek at the Next MSL Generation
Session Chair(s)
J. Lynn Bass
Medical Affairs Lead, Mesoblast, Inc, United States
Medical Science Liaisons reside at the heart of the pharmaceutical industry’s relationships with external thought leaders and experts, and serve as the conduit for the exchange of medical and scientific data through a variety of methods. New technologies and digitalization methods have arisen to improve communication streams, but how effective are these methods as the audience for MSLs changes and evolves? It’s important to assess how these field medical roles are anticipated to mature over the next 3-5 years. This session will seek to interface with Medical Affairs thought leaders who survey MSL trends for the future to assess their impressions of what success may look like for these teams of the future.
Learning Objective : At the conclusion of this session, participants should be able to:
- Debate with Medical Affairs thought leaders on the current value of field MSL teams
- Discuss what new methods and technology may be anticipated for thought leader interactions in the future
- Evaluate what new evolutionary trends to expect for the role of the MSL in the future
Speaker(s)
Sean William Ryan, MD
Consultant, NYO - McKinsey & Company, United States
Speaker
Maureen Feeney, PHARMD, MBA, RPH
Vice President Scientific Communications and Strategic Alliances, Takeda, United States
Speaker
Shannon LaMey, BSN, MS
MSL Field Director, Neuroscience, US Medical Affairs, Genentech, Inc., United States
Speaker
Have an account?